

Eva Kimby

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8654723/publications.pdf>

Version: 2024-02-01

85
papers

4,264
citations

136740

32
h-index

110170

64
g-index

87
all docs

87
docs citations

87
times ranked

4833
citing authors

#	ARTICLE	IF	CITATIONS
1	Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. <i>Blood</i> , 2006, 108, 3295-3301.	0.6	559
2	Tolerability and safety of rituximab (MabThera®). <i>Cancer Treatment Reviews</i> , 2005, 31, 456-473.	3.4	442
3	Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. <i>Lancet</i> , The, 2015, 385, 1873-1883.	6.3	296
4	Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 2853-2858.	0.8	289
5	Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?. <i>Blood</i> , 2014, 124, 3841-3849.	0.6	185
6	Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. <i>Blood</i> , 2016, 128, 1321-1328.	0.6	161
7	A Unifying Microenvironment Model in Follicular Lymphoma: Outcome Is Predicted by Programmed Death-1-Positive, Regulatory, Cytotoxic, and Helper T Cells and Macrophages. <i>Clinical Cancer Research</i> , 2010, 16, 637-650.	3.2	151
8	Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. <i>Blood</i> , 2014, 124, 1404-1411.	0.6	138
9	CD8+ T-Cell Content in Diagnostic Lymph Nodes Measured by Flow Cytometry Is a Predictor of Survival in Follicular Lymphoma. <i>Clinical Cancer Research</i> , 2007, 13, 388-397.	3.2	133
10	Safety of rituximab therapy during the first trimester of pregnancy: a case history. <i>European Journal of Haematology</i> , 2004, 72, 292-295.	1.1	127
11	Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome. <i>Haematologica</i> , 2017, 102, 43-51.	1.7	112
12	Update on Recommendations for Assessing Response from the Third International Workshop on Waldenström's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2006, 6, 380-383.	1.4	107
13	Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 552-560.	0.8	87
14	TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma. <i>Cancer Immunology Research</i> , 2019, 7, 355-362.	1.6	82
15	Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis. <i>Lancet Haematology</i> , the, 2018, 5, e359-e367.	2.2	74
16	Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel – an update. <i>Leukemia and Lymphoma</i> , 2016, 57, 766-782.	0.6	70
17	Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. <i>Haematologica</i> , 2003, 88, 1272-8.	1.7	70
18	Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis. <i>Medical Oncology</i> , 2008, 25, 374-379.	1.2	64

#	ARTICLE	IF	CITATIONS
19	T-Cells Present in Tumour Tissue May Affect the Outcome of Follicular Lymphoma.. Blood, 2004, 104, 3257-3257.	0.6	62
20	Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group. Leukemia and Lymphoma, 2008, 49, 102-112.	0.6	60
21	Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and Tj ETQq1 1 0.784314 rgBT /Overb... 428-435.	2.0	56
22	Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. Blood, 2022, 139, 1684-1693.	0.6	56
23	Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group. Vaccine, 2018, 36, 3701-3707.	1.7	50
24	Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy. Blood, 2019, 134, 353-362.	0.6	45
25	<i>microRNA-34b/c</i> on chromosome 11q23 is aberrantly methylated in chronic lymphocytic leukemia. Epigenetics, 2014, 9, 910-917.	1.3	43
26	T Cells in Tumors and Blood Predict Outcome in Follicular Lymphoma Treated with Rituximab. Clinical Cancer Research, 2011, 17, 4136-4144.	3.2	42
27	Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia. Haematologica, 2015, 100, 511-516.	1.7	42
28	Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up. Journal of Clinical Oncology, 2018, 36, 3315-3323.	0.8	42
29	M7â€FLIPI is not prognostic in follicular lymphoma patients with firstâ€line rituximab chemoâ€free therapy. British Journal of Haematology, 2020, 188, 259-267.	1.2	40
30	Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium. Haematologica, 2017, 102, 1413-1423.	1.7	39
31	Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodies. Vaccine, 2017, 35, 1764-1769.	1.7	36
32	A Systematic Overview of Chemotherapy Effects in Aggressive non-Hodgkin's Lymphoma. Acta OncolÃ³gica, 2001, 40, 198-212.	0.8	34
33	Histamine and Interleukin-2 in Acute Myelogenous Leukemia. Leukemia and Lymphoma, 1997, 27, 429-438.	0.6	33
34	T-Cell Levels Are Prognostic in Mantle Cell Lymphoma. Clinical Cancer Research, 2014, 20, 6096-6104.	3.2	33
35	Beyond immunochemotherapy: Combinations of rituximab with cytokines interferon-Î±2a and granulocyte-macrophage colony stimulating factor. Seminars in Oncology, 2002, 29, 7-10.	0.8	31
36	Clonal cell surface structures related to differentiation, activation and homing in Bâ€cell chronic lymphocytic leukemia and monoclonal lymphocytosis of undetermined significance. European Journal of Haematology, 1989, 43, 452-459.	1.1	30

#	ARTICLE	IF	CITATIONS
37	Prophylactic immunoglobulin therapy in secondary immune deficiency – an expert opinion. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 921-926.	1.3	28
38	Both normal and leukemic B lymphocytes express multiple isoforms of the human <i>Aiolos</i> gene. <i>European Journal of Immunology</i> , 2001, 31, 3469-3474.	1.6	24
39	Two courses of four weekly infusions of rituximab with or without interferon- γ 2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2015, 56, 2598-2607.	0.6	24
40	Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone. <i>Annals of Hematology</i> , 2017, 96, 253-259.	0.8	22
41	Unmet needs in the scientific approach to older patients with lymphoma. <i>Haematologica</i> , 2017, 102, 972-975.	1.7	17
42	Perturbations of the endocannabinoid system in mantle cell lymphoma: correlations to clinical and pathological features. <i>Oncoscience</i> , 2014, 1, 550-557.	0.9	17
43	Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy-free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK). <i>British Journal of Haematology</i> , 2021, 192, 1031-1034.	1.2	14
44	Evaluation of complete response rate at 30 months (CR30) as a surrogate for progression-free survival (PFS) in first-line follicular lymphoma (FL) studies: Results from the prospectively specified Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) analysis with individual patient data (IPD) of 3,837 patients (pts). <i>Journal of Clinical Oncology</i> , 2015, 33, 8504-8504.	0.8	14
45	Ibrutinib induces rapid down-regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia-related genes in blood and lymph nodes. <i>British Journal of Haematology</i> , 2018, 183, 212-224.	1.2	13
46	The simplified follicular lymphoma PRIMA prognostic index is useful in patients with first-line chemo-free rituximab-based therapy. <i>British Journal of Haematology</i> , 2020, 191, 738-747.	1.2	13
47	Prognostic implications of the microenvironment for follicular lymphoma under immunomodulation therapy. <i>British Journal of Haematology</i> , 2020, 189, 707-717.	1.2	13
48	Prognostic factors and primary treatment for Waldenström macroglobulinemia – a Swedish Lymphoma Registry study. <i>British Journal of Haematology</i> , 2018, 183, 564-577.	1.2	12
49	Rituximab Plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. Primary Endpoint Analysis of the Randomized Phase-2 Trial SAKK 35/10. <i>Blood</i> , 2014, 124, 799-799.	0.6	12
50	Management of advanced-stage peripheral T-cell lymphomas. <i>Current Hematologic Malignancy Reports</i> , 2007, 2, 242-248.	1.2	11
51	Higher World Health Organization grades of follicular lymphoma correlate with better outcome in two Nordic Lymphoma Group trials of rituximab without chemotherapy. <i>Leukemia and Lymphoma</i> , 2014, 55, 288-295.	0.6	11
52	The HOVON68 CLL trial revisited: performance status and comorbidity affect survival in elderly patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 594-600.	0.6	10
53	Familial Waldenström's macroglobulinemia and relation to immune defects, autoimmune diseases, and haematological malignancies – A population-based study from northern Sweden. <i>Acta Oncologica</i> , 2016, 55, 91-98.	0.8	9
54	Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 2356-2362.	0.6	9

#	ARTICLE	IF	CITATIONS
55	Immunomodulatory drugs may overcome the negative prognostic role of active Th17 axis in follicular lymphoma: evidence from the SAKK35/10 trial. <i>British Journal of Haematology</i> , 2020, 190, e258-e261.	1.2	9
56	A phase III, randomized, controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL).. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS7131-TPS7131.	0.8	8
57	Rituximab Plus Lenalidomide Versus Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. First Analysis of Survival Endpoints of the Randomized Phase-2 Trial SAKK 35/10. <i>Blood</i> , 2016, 128, 1099-1099.	0.6	7
58	Increasing prevalence of chronic lymphocytic leukemia with an estimated future rise: A nationwide population-based study. <i>American Journal of Hematology</i> , 2020, 95, E36-E38.	2.0	6
59	A clinico-molecular predictor identifies follicular lymphoma patients at risk of early transformation after first-line immunotherapy. <i>Haematologica</i> , 2019, 104, e460-e464.	1.7	5
60	Primary Results of the Health-Related Quality of Life Assessment from the Phase III Gadolin Study of Obinutuzumab Plus Bendamustine Compared with Bendamustine Alone in Patients with Rituximab-Refractory, Indolent Non-Hodgkin Lymphoma. <i>Blood</i> , 2015, 126, 1532-1532.	0.6	5
61	Biological Therapy Doublets: Pairing Rituximab with Interferon, Lenalidomide, and Other Biological Agents in Patients with Follicular Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 221-227.	1.2	4
62	Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials. <i>Blood Advances</i> , 2021, 5, 1737-1745.	2.5	4
63	The role of BAFF and G-CSF for rituximab-induced late-onset neutropenia (LON) in lymphomas. <i>Medical Oncology</i> , 2021, 38, 70.	1.2	4
64	Immunochemotherapy with Low-Dose Subcutaneous Alemtuzumab (A) Plus Oral Fludarabine and Cyclophosphamide (FC) Is Safe and Induces More and Deeper Complete Remissions in Untreated Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) Than Chemotherapy with FC Alone. An Early Analysis of the Randomized Phase-III HOVON68 CLL Trial. <i>Blood</i> , 2011, 118, 290-290.	0.6	3
65	Clinical characteristic and outcome of lymphoplasmacytic lymphoma of non-Waldenstrom macroglobulinemia type: A Swedish lymphoma registry study. <i>British Journal of Haematology</i> , 2022, 196, 1362-1368.	1.2	3
66	Rituximab Purging and Maintenance Improves Progression Free Survival but Not Overall Survival In Patients with Relapsed or Resistant Follicular Lymphoma Prior Receiving An Autologous Transplant. <i>Blood</i> , 2010, 116, 3567-3567.	0.6	2
67	Very Early Effects of Ibrutinib on Tumor and Immune Cells in Blood and Lymph Nodes in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Patients. <i>Blood</i> , 2016, 128, 3235-3235.	0.6	2
68	A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL).. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS8617-TPS8617.	0.8	2
69	Error in a study of the outcome of mantle cell lymphoma: Nordic MCL2 Trial Update: 6-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC+ autologous stem-cell support: still very long survival but. <i>British Journal of Haematology</i> , 2012, 158, 815-816.	1.2	1
70	Incidence and inheritance of hyperphosphorylated paratarg-7 in patients with Waldenstrom's macroglobulinemia in Sweden. <i>Acta Oncologica</i> , 2019, 58, 824-827.	0.8	1
71	Absolute B cell counts in blood predict long-term response in follicular lymphoma patients treated with rituximab without chemotherapy. <i>Annals of Hematology</i> , 2020, 99, 2357-2366.	0.8	1
72	Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study). <i>Blood</i> , 2010, 116, 1376-1376.	0.6	1

#	ARTICLE	IF	CITATIONS
73	Rituximab (R) in Combination with Interferon-a2a (IFN) Versus Single R in Patients with Follicular or Other CD20+ Low-Grade (indolent) Lymphoma. Final Results From a Randomized Phase III Study From the Nordic Lymphoma Group. <i>Blood</i> , 2012, 120, 794-794.	0.6	1
74	Prognostic Assessment In Patients With Chronic Lymphocytic Leukemia (CLL) In Clinical Practice: A European Research Initiative On CLL (ERIC) Survey. <i>Blood</i> , 2013, 122, 4156-4156.	0.6	1
75	Reply to M. Sorigue et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 759-760.	0.8	0
76	Clonal Evolution During Long-Term Follow-up Using Fluorescent in-Situ Hybridisation (FISH) in Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2009, 114, 4218-4218.	0.6	0
77	Several Immune Cell Subsets Are Associated with Outcome in the Microenvironment of Follicular Lymphoma.. <i>Blood</i> , 2009, 114, 3953-3953.	0.6	0
78	Response Is Seen to Conjugate Vaccine but Not to Polysaccharide Vaccine Twelve Months After Rituximab.. <i>Blood</i> , 2009, 114, 2728-2728.	0.6	0
79	Cytogenetic Abnormalities In the Spleen In CLL Patients.. <i>Blood</i> , 2010, 116, 4618-4618.	0.6	0
80	SOX11 Expression Versus Indolent Clinical Course in Mantle Cell Lymphomas in a Population-Based Cohort From the Stockholm Region â€” SOX11 Negative Tumors Are Mostly p53 Positive, Contributing to Shorter Overall Survival,. <i>Blood</i> , 2011, 118, 3651-3651.	0.6	0
81	T-Cell Frequencies In MCL Are Of Prognostic Importance In a Large Population-Based Cohort. <i>Blood</i> , 2013, 122, 1787-1787.	0.6	0
82	Follicular Lymphoma Survival in Sweden in the Rituximab Era. <i>Blood</i> , 2014, 124, 1758-1758.	0.6	0
83	Immune Cell Dynamics in Nordic FL Patients in the SAKK 35/10 Randomized Trial with Rituximab and Lenalidomide. <i>Blood</i> , 2016, 128, 5338-5338.	0.6	0
84	Continuous Increasing Prevalence of Chronic Lymphocytic Leukemia (CLL) with an Estimated Future Riseâ€”a Nationwide Population-Based Study from Sweden. <i>Blood</i> , 2018, 132, 3120-3120.	0.6	0
85	Outcome By Primary Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A Large, Population-Based Study in Sweden. <i>Blood</i> , 2020, 136, 46-47.	0.6	0